There are skin changes that are attributed to the passage of time when in reality they have a very specific hormonal mechanism. Perimenopause and menopause do not age the skin vaguely or gradually: they activate a specific biological cascade that reduces dermal collagen density, alters the lipid barrier, and accelerates systemic oxidative stress. Understanding this mechanism is the first step to responding intelligently.
The Role of Estrogens in the Skin: What is Lost When They Decline
Estrogens, especially estradiol, have specific receptors in the skin: in dermal fibroblasts, keratinocytes, and sebaceous cells. Through these receptors, they directly regulate the synthesis of type I and III collagen, hyaluronic acid production, epidermal thickness, and cutaneous vascularization. They are not an indirect or secondary influence: they are an active regulator of skin biology.
When estradiol levels progressively decline in perimenopause and more abruptly after menopause, all that regulation is reduced. Fibroblasts produce less collagen and less hyaluronic acid. Cell renewal slows down. The lipid barrier becomes less efficient. The result is not just aesthetic: it is structural.
Collagen and Menopause: The Accelerated Decline That Starts Sooner Than You Think
Studies on dermal collagen loss in postmenopausal women are consistent: it is estimated that approximately 30% of the skin's total collagen is lost in the first five years after menopause. This is equivalent to a loss of about 2.1% per year, significantly higher than the 1-1.5% per year that occurs in the premenopausal stage.
What makes this data particularly relevant is that collagen decline begins before menopause is officially diagnosed. During perimenopause—which can last between two and ten years—hormonal fluctuations already affect fibroblast activity. The skin responds to these fluctuations before many women associate them with this stage.
Epidermal Barrier, Dryness, and Reactivity: The Most Common Signs
The skin barrier—the system of intercellular lipids in the stratum corneum that regulates transepidermal water loss—is also affected by the decline in estrogens. The synthesis of ceramides, fatty acids, and cholesterol in the epidermis decreases, which increases transepidermal water loss (TEWL) and reduces the skin's ability to retain hydration.
This explains three very common symptoms at this stage: persistent dryness that does not respond well to conventional moisturizers, increased reactivity to topical products that were previously well-tolerated, and a feeling of skin tightness or discomfort that was not present before. These are not independent symptoms: they are distinct expressions of the same process of barrier function deterioration.
What Research Says About Hydrolyzed Collagen in Menopausal Women
Several clinical trials have specifically evaluated the effect of supplementation with hydrolyzed collagen peptides in postmenopausal women. The results consistently show improvements in elasticity, hydration, and dermal density with continued use for 8 to 12 weeks. The study by Proksch et al. (2014) included women aged 35 to 55 and observed statistically significant improvements in skin elasticity with 2.5 g/day of collagen peptides.
A subsequent study by Schunck et al. (2015) specifically evaluated wrinkle reduction in women aged 45 to 65, observing an average reduction of 20% in periorbital wrinkle depth after 8 weeks of supplementation. LEVIAL's formulation includes 8,000 mg of Peptan® per vial—a widely functional dose according to the ranges evaluated in these studies.
Astaxanthin and Resveratrol: Antioxidants with Evidence in Accelerated Oxidative Stress
Menopause also accelerates systemic oxidative stress. The decline in estrogens reduces endogenous antioxidant activity—estrogens have direct antioxidant properties—and increases the production of reactive oxygen species (ROS). This increased oxidative stress damages existing collagen fibers, activates metalloproteinases (MMPs) that degrade the extracellular matrix, and reduces mitochondrial activity in fibroblasts.
Astaxanthin (AstaReal®, 25 mg/vial in LEVIAL) has documented antioxidant capacity far superior to vitamin E and beta-carotene. Studies by Tominaga et al. have shown improvements in skin elasticity and texture with oral astaxanthin supplementation. Resveratrol (trans-resveratrol 98%, 24.5 mg/vial) activates sirtuins—proteins associated with cell longevity—and has documented anti-inflammatory activity through the inhibition of NF-kB.
Nutricosmetics vs. Topical Cosmetics: Two Complementary Logics
Topical cosmetics act mainly on the epidermis and the superficial layers of the dermis. Topical active ingredients—retinol, vitamin C, peptides, hyaluronic acid—have limited penetration due to the skin's own barrier function, which is precisely designed to prevent the entry of external molecules. This does not make them ineffective: it makes them relevant for what they can achieve.
Nutricosmetics work from the deep dermis upwards, through systemic circulation. Collagen peptides absorbed in the intestine reach dermal fibroblasts via the bloodstream and stimulate endogenous synthesis. It is a completely different, non-competing route of action. In the context of menopause, where changes are systemic and not just superficial, internal support has particularly strong logic.
Keys to Building a Skincare Routine at This Stage
A coherent skincare routine for perimenopausal and menopausal skin should consider three levels: barrier protection (hydration with ceramides and fatty acids, daily photoprotection), renewal stimulation (retinol or bakuchiol, topical vitamin C, gentle AHAs), and sustained internal support (nutricosmetics with hydrolyzed collagen, antioxidants, and mineral cofactors).
The key is not to do more, but to do the right thing consistently. Skin at this stage does not need more layers of cosmetics: it needs the system that supports it from within to be well-nourished. That is the logic behind LEVIAL.
